Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targeting APN/CD13/GP150/LAP1/P150/PEPN for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targeting APN/CD13/GP150/LAP1/P150/PEPN is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug.? It is a recombinant protein coupling the N-terminus of hTNF-¦Á with the C-terminus of a tumour-homing NGR-peptide, which is a ligand of the aminopeptidase N (CD13) overexpressed by endothelial cells of newly formed human tumour blood vessels. Tengonermin modify the tumor microenvironment and increase intra-tumoral chemotherapy penetration and T-cell infiltration.
| Products Name (INN Index) | Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targe |
|---|---|
| INN Name | tengonermin |
| Target | ANPEP |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [NGR peptide 1-6 – TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF- alpha, TNFA)] – trimer |
| VD LC | Fusion – [NGR peptide 1-6 – TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF- alpha, TNFA)] – trimer |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | MolMed?SpA (Milano Italy) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ANPEP |
| Package |
